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Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in the world. Currently, surgical
resection, liver transplantation, and local ablation are considered curative therapeutic practices for HCC. The
diagnosis of HCC without pathologic confirmation is achieved by analyzing serum alpha-fetoprotein (AFP) levels
combined with imaging techniques, including ultrasonography, magnetic resonance imaging, and computerized
tomography. Although progress has been made in the diagnosis and management of HCC, its prognosis remains
dismal. Various new technologies have identified numerous novel biomarkers with potential diagnostic as well as
prognostic value, including Dickkopf-1 and Golgi protein 73. These biomarkers not only help in the early diagnosis
and prediction of prognosis, but also assist in identifying potential targets for therapeutic interventions. In this
article, we provide an up-to-date review of the biomarkers that are used for early diagnosis, prognosis prediction,
and personalized treatment of HCC.
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Hepatocellular carcinoma (HCC) is one of the most
frequently diagnosed cancers worldwide. The disease is
predominant in Asia and Africa, but its incidence is
steadily increasing throughout the rest of the world
[1]. Most HCC develop in patients with a history of
chronic hepatitis or cirrhosis in which there is continuous
inflammation and regeneration of hepatocytes. Unlike
other solid malignancies, the coexistence of inflammation
and cirrhosis makes the early diagnosis and prognostic as-
sessment of HCC much more difficult. This complication
highlights the need to identify valuable biomarkers for the
diagnosis and treatment of HCC.
The proliferation and survival of cancer cells require a
process called oncogene addiction, which is the activa-
tion of specific oncogenes and inactivation of specific
tumor suppressors, such as Rb1 in retinoblastoma [2]
and BRCA1 in breast cancer [3]. However, no specific* Correspondence: zhou.jian@zs-hospital.sh.cn
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reproduction in any medium, provided the oroncogene addictions have been observed in HCC, which
is a complex disease with a variety of underlying patho-
genic anomalies caused by multiple risk factors. The
lack of ideal biomarkers for HCC diagnosis, prognosis,
and therapy has posed a major challenge to HCC
management.
With advances in the understanding of tumor biol-
ogy, interest in identifying molecular biomarkers of
HCC has increased. Over the last decade, a number of
new cutting-edge technologies such as next-generation
sequencing [4,5] and microarray technologies [6-8]
have emerged, leading the search for biomarkers into a
new era of “omics” [9,10]. Using these technologies, it
is now quite easy to examine a whole tumor genome
(including copy number variations, loss of heterogeneity,
aneuploidy, single nucleotide polymorphism) [11-14],
transcriptome [15,16], proteome [17,18], epigenome
[19,20], metabolome [21-23], and miRNA profile [24,25],
and the analysis of tens of thousands of molecular targets
has become affordable and operable. Currently, numerous
circulating markers and tissue markers have been identi-
fied [17,26-30]; however, few biomarkers are acceptable
for clinical utility because of their low predictive accuracy. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of the biomarkers that are used for early diagnosis,
prognosis, and personalized treatment of HCC.
Review
Biomarkers for early diagnosis
The diagnosis of HCC without pathologic confirmation
can be achieved by assessing the serum alpha-fetoprotein
(AFP) level combined with imaging techniques, including
ultrasonography, magnetic resonance imaging, and
computerized tomography [31,32]. However, improve-
ment in early diagnosis is still needed because only 44%
of the patients are diagnosed at a localized disease stage,
and only 30% of patients with HCC are candidates for
potentially curative treatments at the time of diagnosis
[33]. Thus, the discovery of an effective, reliable tool for
early diagnosis of HCC to increase the number of
patients who are suitable for curative treatment will play
a pivotal role in improving HCC patients’ prognosis.
A marker for early diagnosis would meet the follow-
ing requirements: first, it should achieve high accuracy,
which would increase the probability of a diagnosis
being made prior to spread and thus increase the cure
rate; second, specimen collection for detecting the
marker should be easily operable and non-invasive;
and third, the cost-effectiveness should be considered
[34]. Tumor tissue-oriented markers are not highly
practical because not all tumor tissues can be obtained
at an early stage and the invasive procedure may cause
spread of tumor cells. Biomarkers from body fluids
such as serum, plasma, urine, and bile are suitable
candidates for early diagnosis of HCC because they are
easily accessible [35]. In the following section, we list
some important circulating (serum or plasma) markers
for early diagnosis of HCC.
Protein
Since AFP was discovered in the serum of HCC
patients in 1964 [36], it has been regarded as the most
useful serum protein thus far for patients at risk for
HCC [37-39]. However, its sensitivity for detecting
HCC ranges between 25%-60% [39,40], and its specificity
is also low because serum AFP can also be detected in
patients with cirrhosis (11%-47%) and chronic hepatitis
(15%-58%).
In addition to AFP, more than 20 serum proteins
have clinical significance in early diagnosis of HCC
[10,41], among which several proteins are proved to
have advantages over AFP.
DKK1 DKK1 belongs to a family of secreted proteins
that play an important role in HCC progression through
the promotion of cytoplasmic/nuclear accumulation ofbeta-catenin in HCC cells via the Wnt/beta-catenin
signaling pathway [42].
Recently, Shen et al. [41] reported that serum DKK1 is
a promising candidate for HCC diagnosis. The authors
retrospectively assessed serum DKK1 in 1284 patients
(633 with HCC, 171 with chronic HBV infection, 168
with cirrhosis, and 312 healthy controls) and found that
DKK1 has better diagnostic value for HCC than does
AFP, especially for patients with AFP-negative and early
stage HCC. Combined testing of serum DKK1 and AFP
concentrations improved diagnostic accuracy for HCC
versus all controls compared with either test alone.
Nevertheless, DKK1 is not overly specific for HCC diag-
nosis, and a recent study reported that serum DKK1
was also elevated in patients with intrahepatic cholan-
giocarcinoma [43].
Golgi protein 73 (GP73) GP73 is a 73 kDa trans-
membrane glycoprotein that normally resides within the
Golgi complex. It is expressed in normal biliary epithe-
lial cells whereas normal hepatocytes do not express this
protein, and its expression is significantly increased in
liver diseases such as HCC [44].
Serum GP73 is a valuable biomarker for patients with
HCC [45,46]. Mao et al. [46] compared serum GP73 and
AFP in 4217 participants, including 1690 healthy adults,
337 HBV carriers, 512 patients with cirrhosis, 789
patients with HCC, 61 patients with other malignant
liver lesions, 206 patients with benign liver lesions and
622 patients with 14 non-liver cancers. The sensitivity
and specificity of serum GP73 for HCC were 74.6% and
97.4%, respectively, compared with 58.2% and 85.3% for
AFP. The GP73 level significantly increased in patients
with HCC compared with healthy controls, decreased
following surgical resection of HCC lesions and
increased with tumor recurrence. Although the control
group included HBV carriers, this group lacked patients
with chronic hepatitis, whereas most HCC patients have
hepatitis.
Protein induced by vitamin K absence or antagonist
II (PIVKA-II) PIVKA-II, an abnormal prothrombin
discovered in 1984, has been widely proposed to be a
useful HCC biomarker [47]. Takikawa et al. [48] mea-
sured plasma levels of PIVKA-II and AFP in 628
patients with various diseases, including 253 patients
with liver cirrhosis and 116 patients with HCC.
PIVKA-II was detected in 54.3% of patients with HCC,
and the concentration showed a positive correlation
with the tumor size. As a screening test for detecting
HCC, PIVKA-II yielded sensitivity and specificity
values (52.8% and 98.8%, respectively) that were com-
parable with AFP. Beale et al. [49] assessed AFP and
PIVKA-II levels in pre-treatment serum samples from
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AFP and PIVKA-II was better for detecting HCC than
using either AFP or PIVKA-II alone.
Nucleic acids
Nucleic acids, including DNA, RNA, and nucleosomes,
can be detected in the circulation of patients with
HCC, and changes in their levels have been associated
with tumor burden and progression of malignancy
[50]. In the past decade, circulating nucleic acids have
been extensively studied with regard to their diagnostic
significance [51-54]. For instance, plasma AFP mRNA
[28,55] is considered to be a diagnostic marker for
HCC. Accumulating evidence has shown that microRNAs
(miRNAs) play important roles in cancer initiation,
propagation, and progression [56-58]. MiRNA deregula-
tion occurs at early stages of HCC and increases
throughout the various steps of hepatocarcinogenesis
[52]. There are multiple studies on the diagnostic func-
tion of miRNA in HCC diagnosis [52,54,59]. However,
the diagnostic value of miRNAs is limited by one or
more of the following factors: limited number of
screened miRNAs, small sample size, failure to differen-
tiate HCC from hepatitis, and lack of independent
validation.
Recently, we measured plasma miRNA expression pro-
files (723 miRNAs) in a large cohort of 934 participants
that included healthy individuals and patients with
chronic HBV infection, cirrhosis, or HBV-related HCC.
We identified a miRNA panel (miR-122, miR-192, miR-
21, miR-223, miR-26a, miR-27a, and miR-801) that pro-
vided high diagnostic accuracy for discriminating patients
with HCC from the healthy population (AUC= 0.941) and
patients with chronic HBV (AUC= 0.842) or cirrhosis
(AUC= 0.884). This finding led to the conclusion that the
plasma miRNA panel had considerable clinical value for
the early diagnosis of HCC and could help patients who
might have otherwise missed the curative treatment
window benefit from optimal therapy [54].
Prognostic biomarkers
Surgical resection, liver transplantation and local abla-
tion are considered curative therapeutic practices for
HCC. Other modalities, such as targeted therapy and
transarterial chemoembolization (TACE), are palliative
treatments. Despite these curative or palliative treat-
ments, prognosis is still poor due to underlying liver
diseases and the unique biology of HCC. As a result,
biomarkers that better predict patients who are at
higher risk of recurrence and poorer prognosis would
help guide their treatment [26].
A number of biomarkers have been reported to predict
the outcome of these therapies, including CD151 and
CXCL5 for surgical treatment [27,60], AFP and LDH forTACE [61,62], PIVKA-II and VEGF for radiofrequency
ablation (RFA) [63,64], and serum AFP and HBeAg for
percutaneous ethanol injection (PEI) [65-67].
Biomarkers for surgical treatment
Surgical treatment offers a potentially curative option
for HCC patients, but patients’ outcomes are varied due
to differing tumor characteristics. Additionally, the
exact biology of HCC remains poorly understood, thus
making prediction of outcome after surgical resection
very difficult. The prognosis of HCC patients does not
simply reflect the size and number of the tumors;
instead, prognosis is affected by a complex interplay
between known and unknown factors, including tumor
biology, patient condition, etc. [35]. Thus, the ability to
predict which patients have a poor prognosis would help
to assign risk and guide surgery and other treatments.
Circulating biomarkers Circulating biomarkers are
still preferred for prognostic prediction because they
are easily accessible. Serum AFP is commonly used for
diagnosis and surveillance of HCC [37,39] and has been
suggested as an independent indicator for prognosis. HCC
patients with a high serum AFP level tend to have shorter
survival [38,53].
Other circulating factors such as Ang2 [53], VEGF
[53,68,69], HGF [70,71], and TGF-beta [72], are also in-
dependent factors for HCC prognosis. A recent study
proposed that plasma macrophage migration inhibitory
factor (MIF) levels have prognostic value in HCC
patients. Plasma MIF levels have a significant association
with overall survival (OS) and disease-free survival
(DFS) of HCC patients, even in patients with normal
serum AFP levels and Tumor Node Metastasis (TNM)
stage I HCC [73].
Circulating tumor cells (CTCs) may reflect tumor
aggressiveness and serve as a promising candidate for
predicting tumor recurrence and metastasis [74]. How-
ever, their utility is limited due to the rarity of CTCs in
peripheral blood of the patients. Recent technical
advances have made it possible to detect CTCs; there-
fore, their clinical value has been tested in multiple
tumor types, including breast cancer [75], lung cancer
[76], and prostate cancer [77]. Sun et al. proved that
EpCAM-positive CTCs may serve as a prognostic
marker in HCC after curative resection [78].
Tumor tissue biomarkers Research into tumor tissues
can provide direct biological information about the
tumors; thus, the search for tumor biomarkers is crucial.
A plethora of HCC tumor cell-derived biomarkers with
potential prognostic significance have been identified in
recent decades [9,17,26,35,79-81], but consensus could
not be reached.
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for use in determining prognosis [9-11,82]. For instance,
our previous study investigated CXCL5 (epithelial
neutrophil-activating peptide-78) expression in a large
cohort of 919 HCC patients. The results showed that
overexpression of CXCL5 was well correlated with
intratumoral neutrophil infiltration and that CXCL5
overexpression alone or in combination with the pres-
ence of intratumoral neutrophils was an independent
prognostic indicator for OS and cumulative recurrence
in HCC patients [60]. In addition, our institute also
searched extensively for prognostic biomarkers in HCC
patients undergoing liver transplantation [17,83]. By
investigating tumor tissues of 232 HCC patients, we
identified calpain small subunit 1 (Capn4) as an inde-
pendent prognostic factor for recurrence and survival in
HCC patients after liver transplantation [17].
Cancer stem cells (CSCs) may play a pivotal role in
the progression of tumors [84,85]. CSCs represent the
tumorigenic cells that generate tumors via the stem cell
processes of self-renewal and differentiation. CSCs may
persist in tumors as a distinct population and cause
relapse and metastasis by giving rise to new tumors
[86]. Although the existence of CSCs in HCC is still
controversial, several studies have demonstrated the
clinical significance of CSC markers in HCC patients
[10,79]. These markers include CD90 [87], CD133 [29],
CD13 [88], and EpCAM [89].
The role of the microenvironment surrounding tumor
cells for the initiation and progression of HCC is be-
coming increasingly clear [30,90-92]. The tumor micro-
environment, also named the tumor stroma, includes
the extracellular matrix (ECM) and all other non-tumor
cell types within a tumor tissue (e.g. endothelial cells,
fibroblasts, and cells of the immune system). Various
tumor stroma-associated factors, such as regulatory T
cells (Tregs) [93], macrophage colony-stimulating factor
(M-CSF) [94], macrophages [95], and hepatic stellate
cells [96], have been investigated and exhibit significant
prognostic value. For instance, Budhu et al. [97] showed
that a unique inflammation/immune response-related
signature in the venous metastasis-associated liver
microenvironment coincides with elevated expression of
M-CSF and can serve as a superior predictor of HCC
venous metastases when compared with other clinical
prognostic parameters.
Biomarkers for TACE
Although patients with early stage HCC have the
chance to undergo curative treatment, most HCC
patients are still diagnosed at a late stage when curative
treatment is no longer applicable. For these patients,
based on randomized, controlled clinical trials, TACE
may be an effective treatment option for reducingsystemic toxicity, increasing local antitumor effects,
and improving survival [98,99]. However, there are
markedly diverse outcomes after TACE in terms of
treatment response and survival. Therefore, identifying
markers that can predict TACE treatment outcomes
before choosing this treatment option is an important
endeavor.
The most promising prognostic candidates for TACE
are circulating biomarkers. Some studies have reported
that serum AFP [61], circulating nucleosomes [100],
blood neutrophil-to-lymphocyte ratio [101], and lactate
dehydrogenase [62], are prognostic factors for TACE. As
an example, Wang et al. [61] retrospectively studied the
survival of 441 HCC patients (including 139 patients
with normal AFP levels and 302 patients with elevated
AFP levels) after TACE, and found that patients with
normal AFP levels had a better treatment response and
prognosis after TACE than patients with elevated AFP
levels.Personalized therapy
The recent discovery of new therapeutic targets based
on the molecular pathways that are involved in hepato-
carcinogenesis has led to exciting results in targeted
treatment of HCC patients. Investigators have attempted
to select therapeutic options for patients according to
their tumor’s molecular profile, and this treatment
modality will pave the way for personalized treatment of
HCC.Targeted therapy
Targeted therapy that specifically inhibits molecular
abnormalities has emerged as an effective therapeutic
option for malignancies [102,103]. Small molecule
tyrosine kinase inhibitors have great potential for the
treatment of HCC through targeting several growth
factors and their associated signaling pathways (e.g.
EGF/EGFR, VEGF/VEGFR, IGF/IGFR, PDGF, FGF,
RAS/RAF/ERK/MAPK, PI3K/AKT/mTOR, Wnt/beta-
catenin) [104,105]. Currently, nearly 60 reagents are
being investigated for treatment of HCC, but only
sorafenib have been proven effective in patients with
advanced HCC [106].
Sorafenib is an oral multi-kinase inhibitor that com-
petitively inhibits ATP binding to the catalytic domains
of various kinases, such as Raf kinase, VEGFR-2, -3, and
PDGFR, thereby increasing apoptosis and decreasing
angiogenesis and cell proliferation [79,106,107]. How-
ever, no specific marker can guide the use of sorafenib
in HCC; in contrast, HER2 and EGFR expression can
positively predict the therapeutic response rate of tras-
tuzumab in breast cancer and cetuximab in non-small
cell lung cancer, respectively.
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nib, linifanib, brivanib, and regorafenib block a number
of angiogenesis-related signaling pathways, such as
VEGFR, PDGFR, and FGFR [35,104,107]. Although
many clinical trials have been discontinued because of
poor effectiveness or severe adverse effects, these
approaches provide critical insight into the mechanisms
of targeted therapy for HCC and may finally allow us to
optimize the current therapies for this fatal disease.Interferon-alpha
Interferon-alpha is a multifunctional cytokine that post-
pones recurrence of HCC and improves OS in HCC
patients after curative resection [108-110]. However, the
benefit of interferon-alpha therapy is usually modest be-
cause it is not effective for all patients, and it is difficult
to determine which patients will respond well to
interferon-alpha [108,111]. A recent study analyzed the
miRNA profiles of 455 patients with HCC who had
undergone curative tumor resection and assessed the
association of the miRNA profiles with survival and
response to therapy with interferon-alpha. The study
showed that HCC patients whose tumors express low
levels of miR-26 have a better response to interferon-
alpha therapy than patients with high levels, suggesting
that miR-26 expression status could be used as a
predictor of the response to interferon-alpha therapy
[112]. At present, a multicenter, randomized controlled
trial assessing the impact of low miR-26 expression on
interferon-alpha adjuvant therapy for HCC patients is
ongoing in China (NCT01681446, http://clinicaltrials.
gov/ct2/show/NCT01681446?term=jia+fan&rank=3).Conclusions
New technologies have identified numerous novel bio-
markers with potential diagnostic and prognostic value.
Recent advances in identification, isolation, and capture
of tumor-derived microvesicles will reveal new insights
into HCC diagnosis and personalized therapy [113].
Nevertheless, most of these markers have been studied
retrospectively; few prospective trials have evaluated
their clinical significance, or clinical application.
Because HCC is a complex disease with multiple
underlying pathogenic mechanisms caused by a variety
of risk factors, it is difficult to characterize HCC with a
single biomarker. Thus, signatures of a combination of
biomarkers may be more valuable for the diagnosis,
staging, and prognosis of HCC. In the near future,
identifying non-invasive and cost-effective biomarkers
for early diagnosis and personalized treatment of HCC
will be one of the most promising fields of biomarker
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